Ask Warren

Optipharm

153710 · KOSDAQ · ₩153710 · 옵티팜

₩4,345▼ ₩30 (0.69%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩6.6B₩5.4B₩6B₩5.7B₩5.8B₩4.9B₩5.6B₩4.8B
Cost of sales₩4.9B₩4.2B₩4.3B₩4.3B₩4.1B₩4B₩3.9B₩3.5B
Gross profit₩1.7B₩1.1B₩1.6B₩1.3B₩1.7B₩947M₩1.7B₩1.3B
Operating income−₩206M−₩723M−₩321M−₩525M−₩434M−₩1.1B−₩251M−₩546M
Net income₩537M−₩754M−₩2B−₩77M₩668M−₩1.1B−₩1.8B₩243M
Net income to shareholders₩537M−₩754M−₩2B−₩77M₩668M−₩1.1B−₩1.8B₩243M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩40B₩40B₩41B₩42B₩43B₩44B₩43B₩39B
Current assets₩15B₩14B₩15B₩17B₩17B₩18B₩19B₩20B
Cash and equivalents₩4B₩2.2B₩2.3B₩2B₩1.7B₩1.5B₩3.6B₩7.3B
Total liabilities₩15B₩15B₩15B₩17B₩17B₩18B₩16B₩16B
Current liabilities₩13B₩12B₩13B₩13B₩14B₩14B₩13B₩12B
Borrowings₩10B₩10B₩10B₩10B₩11B₩11B₩11B₩11B
Total equity₩25B₩25B₩25B₩26B₩26B₩26B₩27B₩23B
Shareholders' equity₩25B₩25B₩25B₩26B₩26B₩26B₩27B₩23B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩905M−₩741M−₩409M₩315M₩127M−₩1.6B₩172M−₩182M
Capital spending₩113M₩155M₩312M₩70M₩646M₩1.5B₩799M₩281M
Free cash flow₩792M−₩895M−₩720M₩245M−₩519M−₩3.1B−₩626M−₩464M

Consolidated where available. Amounts in won.

Also known as: Optipharm / 옵티팜 / 153710 / KRX:153710

Source: KRX statistical information